Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant atezolizumab in high‑risk renal cell carcinoma after nephrectomy
2016-001881-27Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Atezolizumab with Placebo (2 arms). Primary endpoint: Investigator-assessed disease-free survival. Started Jan 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2016-001881-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001881-27.